Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A
about
Will there ever be a universal Staphylococcus aureus vaccine?Detection of new methicillin-resistant Staphylococcus aureus clones containing the toxic shock syndrome toxin 1 gene responsible for hospital- and community-acquired infections in France.Synthesis and immunogenicity evaluation of Salmonella enterica serovar Paratyphi A O-specific polysaccharide conjugated to diphtheria toxoid.Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoidPhysical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugatesPhenotypic and genotypic characterization of nosocomial Staphylococcus aureus isolates from trauma patients.Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model.Staphylococcus aureus strains that express serotype 5 or serotype 8 capsular polysaccharides differ in virulence.Effect of a trivalent vaccine against Staphylococcus aureus mastitis lymphocyte subpopulations, antibody production, and neutrophil phagocytosisStructural rationale for the modulation of abscess formation by Staphylococcus aureus capsular polysaccharides.Progress in the development of effective vaccines to prevent selected gram-positive bacterial infections.Comparison of immune responses to the O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi adult patients with cholera.Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines.Preparation, characterization, and immunological properties in mice of Escherichia coli O157 O-specific polysaccharide-protein conjugate vaccinesAvailability of complement bound to Staphylococcus aureus to interact with membrane complement receptors influences efficiency of phagocytosis.Antibodies to Staphylococcus aureus serotype 8 capsular polysaccharide react with and protect against serotype 5 and 8 isolatesAntibodies to capsular polysaccharides are not protective against experimental Staphylococcus aureus endocarditis.A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge.Cloning of type 8 capsule genes and analysis of gene clusters for the production of different capsular polysaccharides in Staphylococcus aureus.Molecular characterization and transcriptional analysis of type 8 capsule genes in Staphylococcus aureusStaphylococcus aureus capsular polysaccharides.Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial.Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidatesThe potential economic value of a Staphylococcus aureus vaccine among hemodialysis patients.Natural antibodies in normal human serum inhibit Staphylococcus aureus capsular polysaccharide vaccine efficacy.An antidote for Staphylococcus aureus pneumonia?MsaB activates capsule production at the transcription level in Staphylococcus aureus.Protein antigens increase the protective efficacy of a capsule-based vaccine against Staphylococcus aureus in a rat model of osteomyelitis.The Staphylococcus aureus polysaccharide capsule and Efb-dependent fibrinogen shield act in concert to protect against phagocytosis.Antigenic determinants of Staphylococcus aureus type 5 and type 8 capsular polysaccharide vaccines.Passive immunization with antiserum to a nontoxic alpha-toxin mutant from Staphylococcus aureus is protective in a murine model.Evaluation of serotypes 5 and 8 capsular polysaccharides in protection against Staphylococcus aureus in murine models of infection.Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus.CD4 T cell antigens from Staphylococcus aureus Newman strain identified following immunization with heat-killed bacteria.
P2860
Q26824837-89DE1823-B316-4438-8069-7B5855C16800Q30353240-12E43E39-9DA8-486D-899C-6B917CBF371EQ33577920-0F1F5CA3-289D-457B-9A2A-7DF8A68FFCCFQ33607442-A2BC746A-B483-4F24-B2BE-B6B1FC291F0EQ33613531-32DB52F5-C82A-4097-BE41-65EB7EC66DC5Q33656004-6D4A6CF4-E50B-4A59-9B42-7E1AEB4A1B1CQ33767412-E4B9A339-DD6C-410A-95F6-05C9FAC52393Q33788238-A44E6A02-E73A-4743-BC70-FD1C44996060Q33840647-B2A0A9B4-9DCF-406D-B298-CEED57D07A43Q33931083-40A7DA3F-2305-4BE0-9FD9-4BC3AF2F113BQ34112608-6FC88B46-8884-4794-AD5E-25CA91F50746Q34300720-C5ADBC94-A147-4730-86EB-E704DB5C9DF8Q34541176-A1A32E71-78DD-4DF4-A1F3-76433478471DQ34545082-9364CA6B-2CCB-4FC1-B0D3-72E84345EDE5Q34581644-83FDE2FD-5FA7-47E4-9BEA-8DB928D269F6Q34595644-A09B1B5C-FF79-4517-AA9D-660C47AECE6AQ35382289-FC58FA7D-A64C-45A0-8A42-4C4B0359588AQ35489404-C88F7055-0828-4424-A9D3-D3D1203B7189Q35605034-A0D5D89C-B006-4C34-96D1-B0BCD3DA719EQ35620548-15767E56-774F-4629-AAAA-4B14CA13A64DQ35630504-F1E4FC95-A6B7-4275-94A6-8D9E80216BD4Q35887417-CA5D46BF-CB82-44FC-97D0-8DBE130A0EF8Q35925379-0BA50E8B-F7C7-4658-8C46-B2E806E3709FQ36020705-58810D84-015F-4F0D-B66F-ECBA8C85F774Q36486860-3851F982-6DA5-4799-8864-6360591331FFQ36502876-6D6DF56B-82CA-4F45-8698-A061B3478ABEQ36966028-2F903D21-61EB-473D-809F-1FBD60BEB01CQ37548140-7C456CA2-477A-4C1C-9104-52A2BBC115F4Q38876259-69B89948-CD4C-486E-8877-7242D0D79A8AQ39573071-83B15BB8-6233-46EC-A1B9-B15B27884EE3Q39824967-C66FAFB1-9E5E-463E-8216-277298E6BF89Q40245675-BA57039B-10EF-498B-AE1B-ABA6A9BA1A07Q41871463-808E6367-2A03-47F7-A1DD-8D785617C116Q42109044-11BD978A-910E-4D2B-83E0-9EDF17165849
P2860
Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A
description
1993 nî lūn-bûn
@nan
1993 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի մարտին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Laboratory and clinical evalua ...... inosa recombinant exoprotein A
@ast
Laboratory and clinical evalua ...... inosa recombinant exoprotein A
@en
Laboratory and clinical evalua ...... inosa recombinant exoprotein A
@nl
type
label
Laboratory and clinical evalua ...... inosa recombinant exoprotein A
@ast
Laboratory and clinical evalua ...... inosa recombinant exoprotein A
@en
Laboratory and clinical evalua ...... inosa recombinant exoprotein A
@nl
prefLabel
Laboratory and clinical evalua ...... inosa recombinant exoprotein A
@ast
Laboratory and clinical evalua ...... inosa recombinant exoprotein A
@en
Laboratory and clinical evalua ...... inosa recombinant exoprotein A
@nl
P2093
P2860
P1476
Laboratory and clinical evalua ...... inosa recombinant exoprotein A
@en
P2093
Fitzgerald D
Karakawa WW
Robbins JB
Schneerson R
Shiloach J
P2860
P304
P407
P577
1993-03-01T00:00:00Z